Cargando…
History of cardiovascular events and cardiovascular risk factors among patients initiating strontium ranelate for treatment of osteoporosis
PURPOSE: To estimate the proportion of osteoporosis patients in whom initiating strontium ranelate treatment, under new EMA guidelines, should be contraindicated because of a history of cardiovascular events or risk for cardiovascular events. MATERIALS AND METHODS: This was a retrospective analysis...
Autores principales: | Yu, Jingbo, Tang, Jackson, Li, Zhiyi, Sajjan, Shiva, O’Regan, Christopher, Modi, Ankita, Sazonov, Vasilisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655964/ https://www.ncbi.nlm.nih.gov/pubmed/26604831 http://dx.doi.org/10.2147/IJWH.S88627 |
Ejemplares similares
-
Reasons for not initiating osteoporosis therapy among a managed care population
por: Yu, Jingbo, et al.
Publicado: (2015) -
Gastrointestinal events and association with initiation of treatment for osteoporosis
por: Modi, Ankita, et al.
Publicado: (2015) -
Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis
por: Hiligsmann, M., et al.
Publicado: (2013) -
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
por: Cesareo, Roberto, et al.
Publicado: (2010) -
Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice
por: Donneau, A.-F., et al.
Publicado: (2013)